Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Chief Financial Officer | March 06, 2023 | March 08, 2023 |
| Spyre Therapeutics, Inc.SYRE · Entity 2649 | Chief Financial Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date March 06, 2023 · Filed March 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,115 |
Reported balance
After 2023-03-06 transaction · row 1
1 source rowRow 1 · 2023-03-06 · Sale · Disposed 291 · Balance 59,115 F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units. F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: The transaction was executed in multiple trades in prices ranging from $15.120 to $15.440, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Spyre Therapeutics, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 97,262 |
Reported balance
After 2026-09-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 17,500 · Balance 97,262 |
| Common StockSEC Table I · non-derivative | Direct | 79,762 |
Reported balance
After 2026-09-30 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-30 · Sale · Disposed 17,500 · Balance 79,762 F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 87,262 |
Reported balance
After 2026-10-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 7,500 · Balance 87,262 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. |
| Common StockSEC Table I · non-derivative | Direct | 86,662 |
Reported balance
After 2026-10-01 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-10-01 · Sale · Disposed 600 · Balance 86,662 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 85,162 |
Reported balance
After 2026-10-01 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-10-01 · Sale · Disposed 1,500 · Balance 85,162 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 83,062 |
Reported balance
After 2026-10-01 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-10-01 · Sale · Disposed 2,100 · Balance 83,062 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 79,991 |
Reported balance
After 2026-10-01 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2026-10-01 · Sale · Disposed 3,071 · Balance 79,991 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Common StockSEC Table I · non-derivative | Direct | 79,762 |
Reported balance
After 2026-10-01 transaction · row 8
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 8 · 2026-10-01 · Sale · Disposed 229 · Balance 79,762 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F8: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2033-09-01 | Direct | 319,857 |
Reported balance
After 2026-09-30 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-30 · Exercise / conversion · Disposed 17,500 · Balance 319,857 F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.50 · Expires 2033-09-01 | Direct | 312,357 |
Reported balance
After 2026-10-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-10-01 · Exercise / conversion · Disposed 7,500 · Balance 312,357 F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F2: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
F3: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
F4: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F5: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F6: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F7: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
F8: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer.
F9: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · derivative · entry 10 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 312,357 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F9 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 229 | $93.57 | $21,427.53 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 8 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,762 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F7 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.54 to $93.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F8 · balance_after: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,071 | $92.95 | $285,449.45 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 7 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,991 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F6 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.54 to $93.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,100 | $91.92 | $193,032.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 6 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,062 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.41 to $92.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,500 | $90.27 | $135,405.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 5 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,162 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 600 | $89.07 | $53,442.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,662 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 87,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · derivative · entry 9 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 319,857 Underlying: Common Stock · 17,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 17,500 | $89.89 | $1,573,075.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,762 F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.00 to $90.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 17,500 | $14.50 | $253,750.00 |
DisclosureSEC source: 0001636282-26-000117 · wk-form4_1790990964.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 18,232 | $89.35 | $1,629,029.20 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 6 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,762 F6 · shares: The transaction reported reflects the sale of shares of the Issuer's common stock in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person. F7 · balance_after: Includes 33,738 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of the Issuer's common stock. The RSUs vest on September 1, 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · derivative · entry 7 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 337,357 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F8 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 200 | $89.04 | $17,808.00 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 5 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.69 to $89.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,016 | $88.03 | $177,468.48 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,194 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.64 to $88.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 4,384 | $87.11 | $381,890.24 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,210 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.60 to $87.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 900 | $86.25 | $77,625.00 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,594 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.60 to $86.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2026 Filed Sep 4, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001636282-26-000109 · wk-form4_1788485622.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · derivative · entry 5 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 344,857 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 100 | $97.10 | $9,710.00 |
DisclosureSEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,300 | $96.30 | $221,490.00 |
DisclosureSEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,094 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.85 to $96.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,100 | $95.21 | $485,571.00 |
DisclosureSEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,394 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.84 to $95.83, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 03, 2026 Filed Aug 6, 2026 01:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001636282-26-000100 · wk-form4_1785979922.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · derivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 352,357 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,725 | $88.37 | $152,438.25 |
DisclosureSEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.17 to $89.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,775 | $87.55 | $505,601.25 |
DisclosureSEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,719 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.13 to $88.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 01, 2026 Filed Jul 3, 2026 01:33 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001636282-26-000088 · wk-form4_1783042436.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| June 25, 2026 Filed Jun 27, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · derivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 359,857 Underlying: Common Stock · 15,000 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| June 25, 2026 Filed Jun 27, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 10,000 | $87.14 | $871,400.00 |
DisclosureSEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,994 F1 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.78 to $87.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| June 25, 2026 Filed Jun 27, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 5,000 | $87.12 | $435,600.00 |
DisclosureSEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,994 Read SEC document |
| June 25, 2026 Filed Jun 27, 2026 01:31 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 15,000 | $14.50 | $217,500.00 |
DisclosureSEC source: 0001853327-26-000008 · wk-form4_1782523902.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · derivative · entry 5 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 374,857 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F6 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 3,100 | $72.06 | $223,386.00 |
DisclosureSEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F4 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.54 to $72.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,599 | $70.77 | $183,931.23 |
DisclosureSEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,094 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.38 to $71.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,801 | $69.75 | $125,619.75 |
DisclosureSEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,693 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $69.37 to $70.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 01, 2026 Filed Jun 4, 2026 01:30 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001636282-26-000076 · wk-form4_1780536638.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:35 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001853327-26-000005 · wk-form4_1777685708.xml · derivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 382,357 Underlying: Common Stock · 12,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:35 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 12,500 | $71.37 | $892,125.00 |
DisclosureSEC source: 0001853327-26-000005 · wk-form4_1777685708.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| May 01, 2026 Filed May 2, 2026 01:35 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 12,500 | $14.50 | $181,250.00 |
DisclosureSEC source: 0001853327-26-000005 · wk-form4_1777685708.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001853327-26-000003 · wk-form4_1775266173.xml · derivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 394,857 Underlying: Common Stock · 7,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 1,300 | $49.98 | $64,974.00 |
DisclosureSEC source: 0001853327-26-000003 · wk-form4_1775266173.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.76 to $50.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 6,200 | $49.21 | $305,102.00 |
DisclosureSEC source: 0001853327-26-000003 · wk-form4_1775266173.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,294 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.69 to $49.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2026 Filed Apr 4, 2026 01:29 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 7,500 | $14.50 | $108,750.00 |
DisclosureSEC source: 0001853327-26-000003 · wk-form4_1775266173.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 02:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $14.50 | $0.00 |
DisclosureSEC source: 0001636282-26-000028 · wk-form4_1772591549.xml · derivative · entry 4 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 402,357 Underlying: Common Stock · 2,500 shares Expires 2033-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F5 · derivative.exercise_date: This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 02:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 200 | $41.66 | $8,332.00 |
DisclosureSEC source: 0001636282-26-000028 · wk-form4_1772591549.xml · nonDerivative · entry 3 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,994 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F3 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. F4 · balance_after: Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 02:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 2,300 | $40.56 | $93,288.00 |
DisclosureSEC source: 0001636282-26-000028 · wk-form4_1772591549.xml · nonDerivative · entry 2 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 98,194 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. F2 · price: The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 02:32 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | Exercise / conversionCommon Stock | 2,500 | $14.50 | $36,250.00 |
DisclosureSEC source: 0001636282-26-000028 · wk-form4_1772591549.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025. Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:27 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $30.61 | $0.00 |
DisclosureSEC source: 0001636282-26-000004 · wk-form4_1768357662.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2036-01-09 F1 · derivative.exercise_date: This option represents a right to purchase 140,000 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 22:53 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 18,428 | $16.26 | $299,639.28 |
DisclosureSEC source: 0001636282-25-000095 · wk-form4_1756939995.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,994 F1 · shares: The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person. F2 · price: The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.30, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 67,476 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 21:36 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | GrantStock Option (Right to Buy) · Derivative | 95,500 | $0.00 Strike: $21.66 | $0.00 |
DisclosureSEC source: 0001636282-25-000010 · wk-form4_1737149801.xml · derivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,500 Underlying: Common Stock · 95,500 shares Expires 2035-01-15 F1 · derivative.exercise_date: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 20:04 UTC | Spyre Therapeutics, Inc. SYRE · Entity 2649 | SaleCommon Stock | 18,531 | $28.17 | $522,073.86 |
DisclosureSEC source: 0001636282-24-000062 · wk-form4_1725566647.xml · nonDerivative · entry 1 Burrows Scott L · CIK 0001853327 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,422 F1 · shares: The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,739 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person. F2 · price: The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $27.72 to $28.18, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 101,214 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in three equal installments on each of September 1, 2025, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.